Producing herbal medicines on an industrial scale is challenging. However, a team of bioengineers from Kobe University has ...

personalized medicine; immunotherapy; gene therapy; diagnostic biomarkers; innovative imaging, and clinical genetics. Read More About the Journal ...

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. The loss of insulin leads to the ...

India’s evolving digital health strategy leverages innovative technologies to enhance access to healthcare services. This paper explores the key components of India’s digital health ...

Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, which could lead to advancements in crop resilience and our understanding ...

Queen guitarist Brian May has spent a decade studying the science of bovine tuberculosis, which can be carried by badgers, and has identified a new method of spread ...

White Americans who feel they are in “last place” – falling behind the perceived status of most white, Black, Asian, and Latinx Americans – express the most support for alt-right ideology ...

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials ...

Upon enhanced intracellular delivery, these SiLNPs show clinical promise for protein replacement therapies, regenerative medicine, and CRISPR–Cas-based gene editing applications.

A diagnostic is a test (often using a device) used to assist in the diagnosis of a disease, predict the likelihood of a disease developing or progressing, or predict the likelihood of a response ...

A new Review article series, “AI in Medicine,” explores the role of AI technology in clinical medicine and digital health, and examines the promise and pitfalls of its application across the ...

In the active trial, patients with chronic kidney disease were randomly assigned to receive either empagliflozin (10 mg once daily) or matching placebo and were followed for a median of 2 years ...